Anti-inflammatory agent 17

Anti-inflammatory agent 17 is a potent and orally active anti-inflammatory agent. Anti-inflammatory agent 17 inhibits the release of IL-6 and TNF-α in vitro experiments without cytotoxicity. Anti-inflammatory agent 17 exhibits anti-inflammatory activity in vivo. Anti-inflammatory agent 17 has the potential for the research of Acute lung injury (ALI)[1].

Research Areas >> Inflammation/Immunology

Anti-inflammatory agent 17 (compound 5b) (10 µM; 24 h) displays no toxicity in J774a.1 cells[1]. Anti-inflammatory agent 17 (1.25, 2.5, 5, 10 µM; 2 h) inhibits the production of IL-6 (IC50=8.254 µM) and TNF-α (IC50=2.576 µM) in J774a.1 cells in a dose-dependent manner[1]. Cell Viability Assay[1] Cell Line: J774a.1 cells Concentration: 10 µM Incubation Time: 24 h Result: Displayed no toxicity in J774a.1 cells. Immunofluorescence[1] Cell Line: J774A.1 cells Concentration: 1.25, 2.5, 5, 10 µM Incubation Time: 2 h Result: Inhibited the production of IL-6 (IC50=8.254 µM) and TNF-α (IC50=2.576 µM) in J774a.1 cells in a dose-dependent manner.

Anti-inflammatory agent 17 (20 mg/kg; intragastric administration) exhibits protective effect on LPS (lipopolysaccharide)-induced ALI in mice[1]. Animal Model: C57/BL6 mice[1] Dosage: 20 mg/kg Administration: Intragastric administration Result: Exhibited protective effect on LPS-induced ALI in mice.

[1]. Wang X,et al. Design, synthesis and bioactivity evaluation of fisetin derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury. Bioorg Med Chem. 2021; 49:116456.